Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company, which is engaged in the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. It manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. It has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.
企業コードCUPR
会社名Cuprina Holdings (Cayman) Ltd
上場日Apr 10, 2025
最高経営責任者「CEO」Mr. Yong Qi (David) Quek
従業員数14
証券種類Ordinary Share
決算期末Apr 10
本社所在地Block 1090
都市
証券取引所NASDAQ Capital Market Consolidated
国Singapore
郵便番号169201
電話番号6585127275
ウェブサイトhttps://cuprina.com/
企業コードCUPR
上場日Apr 10, 2025
最高経営責任者「CEO」Mr. Yong Qi (David) Quek
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし